CSF2 and melanoma: Furthermore, an active phase 1 pilot study (NCT03003676) is testing the safety of ONCOS-102, an engineered oncolytic adenovirus expressing GM-CSF, followed by pembrolizumab, in patients with advanced or unresectable melanoma progressing after PD-1 blockade.